Ethics Subcommittee, Advisory Committee to the Director (ACD), Centers for Disease Control and Prevention (CDC), 38086 [E7-13523]
Download as PDF
<![CDATA[
38086
Federal Register / Vol. 72, No. 133 / Thursday, July 12, 2007 / Notices
N.V.,all of Brussels, Belgium, Fortis
Bank Nederland (Holding) N.V.,
Utrecht, Netherlands, and RFS Holdings
B.V., Amsterdam, Netherlands, is
revised to read as follows:
A. Federal Reserve Bank of Boston
(Richard Walker, Community Affairs
Officer) P.O. Box 55882, Boston,
Massachusetts 02106-2204:
1. Royal Bank of Scotland Group, plc,
Edinburgh, Scotland, Banco Santander
Central Hispano, S.A., Madrid, Spain,
Santander Holanda B.V., Delft,
Netherlands, Fortis N.V., Utrecht,
Netherlands, Fortis S.A./N.V.,Fortis
Brussels, S.A./N.V., Fortis Bank, all of
Brussels, Belgium, Fortis Bank
Nederland (Holding) N.V., Utrecht,
Netherlands, and RFS Holdings B.V.,
Amsterdam, Netherlands; to control
ABN AMRO Holding N.V. Amsterdam,
Netherlands, and thereby indirectly
acquire ABN AMRO North American
Holding Company, LaSalle Bank
Corporation, LaSalle Bank National
Association, all of Chicago, Illinois, and
LaSalle Bank Midwest National
Association, Troy, Michigan. In
connection with this proposal Fortis
Bank Nederland (Holding) N.V.,
Santander Holand B.V. and RFS
Holdings B.V. have applied to become
bank holing companies.
In addition, each of The Royal Bank
of Scotland Group, plc, The Royal Bank
of Scotland plc, RBSG International
Holdings Limited, all of Edinburgh,
Scotland, and Citizens Financial Group,
Inc., Providence, Rhode Island, has
applied to acquire control of ABN
AMRO North American Holding
Company, LaSalle Bank Corporation,
LaSalle Bank National Association, and
LaSalle Bank Midwest National
Association in a transfer subsequent to
the acquisition of control of ABN AMRO
Holding N.V.
Comments on this application must
be received by July 25, 2007.
Board of Governors of the Federal Reserve
System, July 9, 2007.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E7–13530 Filed 7–11–07; 8:45 am]
rwilkins on PROD1PC63 with NOTICES
BILLING CODE 6210–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Food and Drug Administration
Ethics Subcommittee, Advisory
Committee to the Director (ACD),
Centers for Disease Control and
Prevention (CDC)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), CDC announces the
following meeting for the
aforementioned subcommittee.
Times and dates: 1 p.m.–5:30 p.m., August
9, 2007. 8:30 a.m.–3:30 p.m., August 10,
2007.
Place: CDC, 1825 Century Center,
Conference Room 1 A/B, Atlanta, GA 30345.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 75 people. To
accommodate public participation in the
meeting, a conference telephone line will be
available. The public is welcome to
participate during the public comment
periods by calling (866) 919–3560 and
entering code 4168828. The public comment
periods are tentatively scheduled from 4:45
p.m.–5 p.m. on August 9, 2007 and from 3
p.m.–3:15 p.m. on August 10, 2007.
Purpose: The Ethics Subcommittee will
provide counsel to the ACD, CDC regarding
a broad range of public health ethics
questions and issues arising from programs,
scientists, and practitioners.
Matters To Be Discussed: Agenda items
will include: Ethical Guidance for Public
Health Emergency Preparedness and
Response, Ethical Issues relating to CDC
Partnerships, Public Health Ethics and
Genomics, Ethical Guidance for NonResearch Data Collections, and Updates on
Ethical Issues relating to Pandemic Influenza
Preparedness. Agenda items are subject to
change as priorities dictate.
For security reasons, members of the
public interested in attending the meeting
should contact the person below. The
deadline for notification of attendance is
August 2, 2007.
Contact Person for More Information: Drue
Barrett, Ph.D., Designated Federal Official,
Ethics Subcommittee, CDC, 1600 Clifton
Road, NE., M/S D–50, Atlanta, Georgia
30333. Telephone (404) 639–4690. E-mail:
dbarrett@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: July 5, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office Centers for Disease Control
and Prevention (CDC).
[FR Doc. E7–13523 Filed 7–11–07; 8:45 am]
BILLING CODE 4163–18–P
VerDate Aug<31>2005
16:42 Jul 11, 2007
Jkt 211001
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
Antiviral Drugs Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Antiviral Drugs
Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on September 5, 2007, from 8 a.m.
to 4 p.m. and on September 6, 2007,
from 9 a.m. to 1 p.m.
Location: On September 5, 2007, the
committee will meet at the Hilton
Washington DC/Silver Spring, The
Ballrooms, 8727 Colesville Rd., Silver
Spring, MD. The hotel telephone
number is 301–589–5200. On September
6, 2007, the committee will meet in
closed session at FDA, White Oak
Headquarters, rm. 2046, 10903 New
Hampshire Ave., Silver Spring, MD.
Contact Person: Cicely Reese, Center
for Drug Evaluation and Research (HFD–
21), Food and Drug Administration,
5600 Fishers Lane (for express delivery,
5630 Fishers Lane, rm. 1093), Rockville,
MD 20857, 301–827–7001, FAX: 301–
827–6776, e-mail:
Cicely.Reese@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512531. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On September 5, 2007, the
committee will discuss new drug
application (NDA) 22–145, raltegravir
potassium, integrase inhibitor 400
milligram tablets, Merck & Co., Inc., for
the treatment of Human
Immunodeficiency Virus-1 (HIV–1)
infection in combination with other
E:\FR\FM\12JYN1.SGM
12JYN1
]]>Agencies
[Federal Register Volume 72, Number 133 (Thursday, July 12, 2007)]
[Notices]
[Page 38086]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-13523]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Ethics Subcommittee, Advisory Committee to the Director (ACD),
Centers for Disease Control and Prevention (CDC)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), CDC announces the following meeting for
the aforementioned subcommittee.
Times and dates: 1 p.m.-5:30 p.m., August 9, 2007. 8:30 a.m.-
3:30 p.m., August 10, 2007.
Place: CDC, 1825 Century Center, Conference Room 1 A/B, Atlanta,
GA 30345.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 75 people. To
accommodate public participation in the meeting, a conference
telephone line will be available. The public is welcome to
participate during the public comment periods by calling (866) 919-
3560 and entering code 4168828. The public comment periods are
tentatively scheduled from 4:45 p.m.-5 p.m. on August 9, 2007 and
from 3 p.m.-3:15 p.m. on August 10, 2007.
Purpose: The Ethics Subcommittee will provide counsel to the
ACD, CDC regarding a broad range of public health ethics questions
and issues arising from programs, scientists, and practitioners.
Matters To Be Discussed: Agenda items will include: Ethical
Guidance for Public Health Emergency Preparedness and Response,
Ethical Issues relating to CDC Partnerships, Public Health Ethics
and Genomics, Ethical Guidance for Non-Research Data Collections,
and Updates on Ethical Issues relating to Pandemic Influenza
Preparedness. Agenda items are subject to change as priorities
dictate.
For security reasons, members of the public interested in
attending the meeting should contact the person below. The deadline
for notification of attendance is August 2, 2007.
Contact Person for More Information: Drue Barrett, Ph.D.,
Designated Federal Official, Ethics Subcommittee, CDC, 1600 Clifton
Road, NE., M/S D-50, Atlanta, Georgia 30333. Telephone (404) 639-
4690. E-mail: dbarrett@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: July 5, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and Services Office Centers for
Disease Control and Prevention (CDC).
[FR Doc. E7-13523 Filed 7-11-07; 8:45 am]
BILLING CODE 4163-18-P
